HOME >> BIOLOGY >> NEWS
New multiple myeloma treatment induced total remission in 33 percent of patients

A study, lead by Dr. Laura Rosiol, researcher of the Haematooncology Group of Hospital Clnic-IDIBAPS (Barcelona) in collaboration with Dr Joan Blade, researcher in the same group, administered alternately two drugs (Bortezomid and Dexamethasone) before conducting autologous bone marrow transplantations. The aim of this second phase trial was to assess the treatments overall response rate, its toxicity in patients, the possibility of recovery of innate stem cells, and the response kinetics which is calculated by measuring M-protein concentrations in serum and urine. M-protein is associated with myeloma presence.

This research work, conducted in the frame of the PETHEMA network, has been coordinated by Hospital Clnic de Barcelona and had the participation of eight more Spanish hospitals: Hospital Germans Trias i Pujol, Hospital Clnico Salamanca, Hospital de Sant Pau, Hospital Clnico de Madrid, Hospital La Princesa, Hospital 12 de Octubre and Hospital La Fe. A total of 40 patients between 41 and 65 years with newly diagnosed multiple myeloma participated in this study. All of them underwent six treatment cycles with a 10-day break between each, and were administered Bortezomid or Dexamethasone alternately.

This study has showed very relevant facts. The first notable fact is that there was a global reduction of M-protein concentration in both urine and plasma, reflecting a global reduction of tumour cells. Thus, a highly efficient anti-myeloma effect was observed, and the post autologous transplantation response index was favourable: a 94% response, one third of which (33%) was of complete response (CR) and 22% was a very good partial response (VGPR).

Another surprising result was the speed at which the effect was achieved i.e. the highest reduction in M-protein was detected within the first four treatment cycles. It should be mentioned that the first two cycles already caused an 82% reduction. These results set the base for furt
'"/>

Contact: Anna Ramon
comunicacio@clinic.ub.es
34-932-275-700
IDIBAPS - Institut d'Investigacions Biomdiques August Pi i Sunyer
4-Jun-2007


Page: 1 2

Related biology news :

1. Diverse genetic abnormalities lead to NF-κB activation in multiple myeloma
2. Research teams uncover risk genes for multiple sclerosis
3. First new multiple sclerosis gene found in 30 years
4. After a decades-long search, scientists identify new genetic risk factors for multiple sclerosis
5. Risk genes for multiple sclerosis uncovered
6. Obesity found to be a risk factor for multiple myeloma
7. Kaposi sarcoma arises independently from multiple cells
8. New collaborative research reveals chimpanzees can sustain multiple-tradition cultures
9. Testosterone may help men with multiple sclerosis
10. New imaging approach promises insights into multiple sclerosis
11. Study identifies multiple genetic risk factors for prostate cancer

Post Your Comments:
(Date:8/25/2015)... SALT LAKE CITY and BELLEVUE, ... a global leader in advanced robotic systems, announced today ... first-of-its-kind robotic unmanned ground vehicle (UGV), at the National ... Lake City.  The Guardian S is ... is the culmination of years of research and in-field ...
(Date:8/20/2015)... 2015   Sensory, Inc ., a Silicon ... experience and security of consumer electronics through state-of-the-art ... its TrulySecure™ is the first multimodal ... FIDO Certified™. The FIDO (Fast Identification ... FIDO UAF (Universal Authentication Framework) 1.0 specifications, which ...
(Date:8/18/2015)... 17, 2015 Research and Markets ( ... "Global Biometric Authentication & Identification Market: Focus ... Forecast, 2015-2020" report to their offering. ... systems market is expected to grow at an ... and generate over $25 billion (approximately) by 2020 ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2
(Date:8/31/2015)... , Aug. 31, 2015 Research and ... the "Israel Biomedical Sensors Market - Growth, Trends ... The Israel Biomedical Sensors market is estimated ... 3.73% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
(Date:8/31/2015)... SYDNEY , Aug. 31, 2015  US-Australian ... NVGN ) today confirmed its comprehensive scientific ... ground-breaking technology platforms in areas of unmet patient ... through the remaining preclinical projects prior to entering ... lead compounds. Acting Chief Executive Officer, ...
(Date:8/31/2015)... ... August 31, 2015 , ... Regulatory agencies have acknowledged ... development approval process. Thus, innovator companies must understand what will be needed in ... CMO, has been hosting multiple educational panels and seminars for experts to share ...
(Date:8/28/2015)... 2015 Research and Markets ... "Global & USA BioSimilar Market Analysis to 2021" ... awaited US Biosimilar market will be initiated in September ... How will the global market react? Will biosimilars explode ... could save the US economy up to $250 billion ...
Breaking Biology Technology:Israel Biomedical Sensors Market 2015 - Growth, Trends & Forecasts to 2020 2Novogen Announces The Outcome Of A Comprehensive Science Review 2Novogen Announces The Outcome Of A Comprehensive Science Review 3Novogen Announces The Outcome Of A Comprehensive Science Review 4Novogen Announces The Outcome Of A Comprehensive Science Review 5Novogen Announces The Outcome Of A Comprehensive Science Review 6Regis Shares Expert Advice on Impurities in Drug Development 2Regis Shares Expert Advice on Impurities in Drug Development 3Global & USA BioSimilar Market Analysis Report 2015-2021 2Global & USA BioSimilar Market Analysis Report 2015-2021 3
Cached News: